![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-Term Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Compared to
Efavirenz/Emtricitabine/Tenofovir DF in HIV-1-Infected, Treatment-Naïve, Black Versus Non-Black Subjects
|
|
|
Reported by Jules Levin
IDSA Oct 2-6 2013 San Francisco, CA
D Hardy1, P Ruane2, K Workowski3, P Shalit4, G Crofoot5, T Nguyen6, H Liu6, M Rhee6, D Piontkowsky6, and J Szwarcberg6
1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Peter J. Ruane, MD, Inc., Los Angeles, CA; 3Emory University, Atlanta, GA; 4Peter Shalit, MD, Seattle, WA; 5Gordon E. Crofoot, MD, Houston, TX; 6Gilead Sciences Inc., Foster City, CA
![ID1.gif](../images/100713/100713-2/ID1.gif)
![ID2.gif](../images/100713/100713-2/ID2.gif)
![ID3.gif](../images/100713/100713-2/ID3.gif)
![ID4.gif](../images/100713/100713-2/ID4.gif)
![ID5.gif](../images/100713/100713-2/ID5.gif)
![ID6.gif](../images/100713/100713-2/ID6.gif)
![ID7.gif](../images/100713/100713-2/ID7.gif)
![ID8.gif](../images/100713/100713-2/ID8.gif)
![ID9.gif](../images/100713/100713-2/ID9.gif)
![ID10.gif](../images/100713/100713-2/ID10.gif)
![ID11.gif](../images/100713/100713-2/ID11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|